Bladder

Bladder conditions at the BVA cover a wider range of pathology than most condition categories. The umbrella includes bladder cancer, neurogenic bladder, interstitial cystitis, post-surgical bladder dysfunction, urinary incontinence from any cause, and bladder injury residuals. In our analysis of 540 BVA cases tagged with bladder as the primary condition, the grant rate is 48.0 percent and the denial rate is 45.7 percent, close to a coin flip.

What's distinctive about bladder claims is the connection-type distribution. Presumptive service connection covers 171 of the 540 cases, substantially higher than most genitourinary conditions outside of prostate cancer. The herbicide framework accounts for 155 of those presumptive-coded cases, with Camp Lejeune adding 37 and other exposure theories rounding out the smaller subsets. Those dataset labels describe theories invoked in the decisions; the current particulate-matter bladder-cancer presumption is the separate rule in 38 CFR § 3.320a.

The rating framework runs through 38 CFR § 4.115a, the same genitourinary residuals criteria that govern prostate post-treatment ratings. Voiding dysfunction is the predominant rating basis. Urinary frequency and urinary tract infection are the secondary categories.

TL;DR

• 540 bladder cases in our BVA dataset. Outcomes: 48.0% granted, 45.7% denied, 6.3% remanded. The remand rate is unusually low for the urological cluster.
• Bladder conditions are rated under DC 7517 (bladder injuries), DC 7518 (bladder stricture), DC 7519 (bladder fistula), DC 7520 (bladder removal), DC 7522 (penis deformity), DC 7527 (already covered on the prostate page), DC 7528 (malignant neoplasms, the same code that covers prostate cancer), and DC 7542 (neurogenic bladder).
• Most non-cancer bladder conditions get rated through the voiding dysfunction, urinary frequency, or urinary tract infection criteria at 38 CFR § 4.115a, the same framework that covers prostate residuals.
• Presumptive service connection grants at 63.7%. Direct grants at 54.9%. Secondary grants at 43.3%. Current exact bladder-cancer lanes include 38 USC § 1116 for herbicide-covered service, 38 CFR §§ 3.307(a)(7) and 3.309(f) for Camp Lejeune, and 38 CFR § 3.320a for qualifying Gulf War and post-9/11 service.
• Strong nexus opinions grant at 97.6%. Weak nexus grants at 0%. The opinion-quality cliff is steep but matters less here because so many cases run through the presumptive lanes where nexus isn't required.
• The modal post-treatment rating among granted cases is 60 percent (27 cases), followed by 100 percent (24 cases), 40 percent (22 cases), and 20 percent (24 cases). Bladder ratings cluster higher than most conditions because severe voiding dysfunction and bladder cancer both reach the 60 to 100 percent tiers.
• C&P inadequacy rate is 35 percent, below the BVA average. The bladder DBQ is more mechanical than most genitourinary evaluations.

The Bladder Diagnostic Codes

Bladder conditions span more diagnostic codes than most veterans realize. The ones that matter for BVA-level claims:

DC 7517: Injury of the bladder

Rated by analogy through the voiding dysfunction criteria at 38 CFR § 4.115a. This is the catch-all for bladder injury residuals: trauma during service, surgical complications, post-fusion injuries. The rating depends on which symptom dominates.

DC 7518: Stricture of the urethra

Bladder outlet obstruction from urethral stricture. Rated by analogy through voiding dysfunction.

DC 7519: Fistula of bladder

Connection between the bladder and another structure (rectum, vagina, skin). Rated by analogy through voiding dysfunction.

DC 7520: Removal of half or more of the bladder

A 30 percent minimum rating for partial bladder removal, with the actual rating based on the residuals via voiding dysfunction.

DC 7522: Erectile dysfunction, with or without penile deformity

Current DC 7522 assigns a 0-percent schedular rating for erectile dysfunction with or without penile deformity. The former 20-percent deformity criterion was removed in 2021. When ED is service connected as a bladder-condition or treatment residual, VA should also review possible SMC under 38 CFR § 3.350 based on qualifying loss or loss of use.

DC 7528: Malignant neoplasms of the genitourinary system

This is the bladder cancer code. Same regulatory mechanics as prostate cancer: 100 percent during active treatment, mandatory six-month re-evaluation, then residuals-based rating. Bladder cancer is presumptive for qualifying Camp Lejeune veterans under 38 CFR §§ 3.307(a)(7) and 3.309(f), for veterans with herbicide-covered service under 38 USC § 1116, and for veterans who meet 38 CFR § 3.320a.

DC 7542: Neurogenic bladder

Rated through voiding dysfunction. Neurogenic bladder is bladder dysfunction caused by neurological damage, most often from spinal cord injury, multiple sclerosis, diabetes, or spina bifida. The rating focuses on the urinary symptoms rather than the underlying neurological condition (which is typically rated separately).

The Voiding Dysfunction Framework

For most non-cancer bladder conditions, the actual rating comes from the voiding dysfunction criteria at 38 CFR § 4.115a:

• 20%: Requiring the wearing of absorbent materials which must be changed less than 2 times per day
• 40%: Requiring the wearing of absorbent materials which must be changed 2 to 4 times per day
• 60%: Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than 4 times per day

The 60 percent tier shows up frequently in our dataset because veterans with severe bladder dysfunction (post-surgical, neurogenic, or post-radiation) often clear the "more than 4 times per day" threshold. Veterans who use intermittent self-catheterization or who have indwelling catheters get rated under the appliance criteria, which lands them at 60 percent automatically.

The alternative rating paths through urinary frequency (10 to 40 percent based on voiding intervals) and urinary tract infection (10 to 30 percent based on infection frequency and treatment intensity) apply when those symptoms are predominant rather than incontinence.

The Camp Lejeune Presumptive Path

The VA disability presumption is in 38 CFR §§ 3.307(a)(7) and 3.309(f). It covers veterans, former reservists, and former National Guard members who served at Camp Lejeune or Marine Corps Air Station New River between August 1, 1953, and December 31, 1987, for at least 30 cumulative days, subject to the regulation's requirements. The Camp Lejeune Justice Act of 2022 created a separate federal cause of action and is not the source of this VA disability presumption.

The covered presumptive conditions explicitly include bladder cancer. They don't directly cover non-cancer bladder conditions like interstitial cystitis or neurogenic bladder, but the presumption framework can support secondary claims where a non-cancer bladder condition is medically connected to a presumptive condition.

In our dataset, 37 of 171 presumptive-category bladder cases involve Camp Lejeune. The grant pattern for these cases is favorable: once qualifying service is documented and the diagnosis is established, the presumption removes most of the heavy lifting on nexus.

For a previously denied Camp Lejeune bladder-cancer claim, the next review path depends on the date and basis of the prior decision and the evidence now available. The current §§ 3.307(a)(7) and 3.309(f) requirements control the disability presumption.

The Herbicide Lane and Bladder Cancer

The current herbicide statute, 38 USC § 1116(a)(2), lists bladder cancer as a presumptive disease for veterans with qualifying covered service. Congress added bladder cancer through the FY2021 NDAA, not the PACT Act. The current § 3.309(e) table has lagged some later statutory additions, so § 1116 is the controlling citation for bladder cancer rather than a claim that the current regulatory table itself lists it.

In our dataset, 155 of the 171 presumptive-category bladder cases (91 percent) invoke the herbicide framework. The presumption covers bladder cancer specifically, not BPH, interstitial cystitis, or other non-cancer bladder conditions. But the cascade from bladder cancer to post-treatment bladder dysfunction means many veterans rated for residuals are tracing the underlying service connection back to the cancer presumption.

The cancer pathway through DC 7528 produces the same rating mechanics as prostate cancer: 100 percent during active treatment, mandatory six-month re-evaluation, then residuals-based rating. The residuals after bladder cancer treatment (cystectomy, BCG immunotherapy, radiation) often produce severe voiding dysfunction that clears the 60 percent tier or higher.

The 2025 Toxic-Exposure Presumption Under 38 CFR § 3.320a

VA added 38 CFR § 3.320a through an interim final rule effective January 2, 2025. The rule presumes service connection for urinary bladder cancer, including overlapping sites of the bladder, for a covered veteran. It also covers ureter cancer, including the ureteric orifice and urachus.

The regulation defines its own covered-service groups: service in the Southwest Asia theater of operations or Somalia, including airspace above both, during the Persian Gulf War on or after August 2, 1990; and service in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, or Uzbekistan, including airspace, on or after September 11, 2001.

Section 1119 can establish presumed toxic exposure for covered PACT Act service, but it is not the bladder-cancer disease presumption. For this path, cite § 3.320a. The original 2022 list in § 1120 did not itself name bladder cancer; VA added this presumption in 2025 using its additional-presumption authority.

What Wins Bladder Claims at the Board

A few patterns we see consistently in granted cases:

Documented qualifying service for a presumptive lane. Herbicide-covered service for the 38 USC § 1116 presumption. Camp Lejeune or MCAS New River service meeting §§ 3.307(a)(7) and 3.309(f). Covered Gulf War or post-9/11 service meeting § 3.320a, whose bladder-cancer presumption became effective January 2, 2025.

Pathology confirmation for bladder cancer cases. Biopsy results, cystoscopy with biopsy findings, or surgical pathology. Veterans with elevated urinary markers or suspicious imaging but no biopsy-confirmed cancer don't qualify for DC 7528.

Voiding dysfunction documentation. For non-cancer bladder conditions, the rating analysis depends on documented absorbent material use frequency, intermittent self-catheterization, or appliance use. The treating urologist's records or the C&P examiner's documentation needs to engage with these specific criteria.

Neurogenic bladder underlying-condition documentation. For veterans claiming bladder dysfunction secondary to a service-connected neurological condition (spinal cord injury, multiple sclerosis, diabetes), the medical opinion needs to establish the mechanism. The Board generally accepts well-documented neurogenic bladder secondary claims, but the supporting clinical evidence has to be clear.

Engagement with the residuals framework post-treatment. For veterans with cancer history, the rating analysis at the six-month re-evaluation depends on what the residuals documentation shows. Specific symptom documentation is what supports the higher residuals tiers.

Bottom Line

Bladder conditions are rated under DC 7517 through DC 7542 in the genitourinary chapter at 38 CFR § 4.115b. Most non-cancer bladder conditions get rated through the voiding dysfunction, urinary frequency, or urinary tract infection criteria at 38 CFR § 4.115a. In our BVA dataset of 540 cases, the grant rate is 48.0 percent. Exact bladder-cancer presumptions include 38 USC § 1116 for qualifying herbicide service, 38 CFR §§ 3.307(a)(7) and 3.309(f) for qualifying Camp Lejeune service, and 38 CFR § 3.320a for its covered Gulf War and post-9/11 groups. The § 3.320a presumption became effective January 2, 2025; it was not part of the original 2022 § 1120 disease list. Bladder ratings cluster higher than most condition categories: the modal residuals rating is 60 percent, and a 100 percent rating shows up in 24 cases largely from active-treatment bladder cancer or other qualifying rating criteria. Strong nexus opinions grant at 97.6 percent versus 0 percent for weak nexus.

Methodology and Limitations

• Data source: 38 CFR § 4.115b DC 7517 through DC 7542, 38 CFR § 4.115a (genitourinary residuals criteria), 38 USC § 1116 (herbicide presumption), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune), 38 CFR § 3.320a (urinary bladder and ureter cancer, including cancer of the ureteric orifice and urachus, effective January 2, 2025), 38 USC §§ 1119 and 1120 (related PACT Act authorities and limits), and Claim Raven's analysis of BVA decisions tagged with bladder as the primary condition.
• Sample size: 540 BVA decisions involving the bladder as the primary condition. Outcomes split granted 48.0% (259), denied 45.7% (247), remanded 6.3% (34). Connection-type, nexus-quality, denial-reason, and rating-tier breakdowns are coded from the Board's discussion in each decision.
• Limitations: The dataset captures BVA-level decisions. Bladder claims granted at the regional office without appeal aren't in the sample. Bladder cancer and non-cancer bladder conditions are coded together in this analysis; the rating mechanics differ significantly between the two. Current statutory and regulatory text controls each presumptive path. Neurogenic bladder is often coded under the underlying neurological condition rather than under the bladder code in some BVA decisions; our analysis captures cases where the bladder is the primary tag. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.